Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies

Antimicrob Agents Chemother. 2009 Feb;53(2):785-7. doi: 10.1128/AAC.00891-08. Epub 2008 Dec 1.

Abstract

Imipenem plasma concentrations were analyzed in 57 febrile neutropenic patients using the NONMEM program. The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC(90) = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Female
  • Glomerular Filtration Rate
  • Guidelines as Topic
  • Hematologic Neoplasms / complications*
  • Hematologic Neoplasms / drug therapy
  • Humans
  • Imipenem / administration & dosage*
  • Imipenem / pharmacokinetics
  • Imipenem / therapeutic use*
  • Male
  • Middle Aged
  • Models, Biological
  • Neutropenia / chemically induced*
  • Neutropenia / complications*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Imipenem